The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosis

References

• Ozenci V, Kouwenhoven M, Link H. Cytokines in multiple sclerosis: methodological aspects and pathogenic implications. Mult Scler 2002;8:396–404
   Google Scholar
• Conlon P, Oksenberg JR, Zhang J, et al. The immunobiology of multiple sclerosis: an autoimmune disease of the central nervous system. Neurobiol Dis 1999;6:149–66
   PubMed Web of Science ®Google Scholar
• Seamons A, Perchellet A, Goverman J. Immune tolerance to myelin proteins. Immunol Res 2003;28:201–21
   Google Scholar
• Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995;80:695–705
   PubMed Web of Science ®Google Scholar
• Navikas V, Link H. Review: cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res 1996;45:322–33
   PubMed Web of Science ®Google Scholar
• Sadovnick AD, Ebers GC. Epidemiology of multiple sclerosis: a critical overview. Can J Neurol Sci 1993;20:17–29
   PubMed Web of Science ®Google Scholar
• Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000;343:938–52
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907–11
   Google Scholar
• Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133–46
   Google Scholar
• Swanson JW. Multiple sclerosis: update in diagnosis and review of prognostic factors. Mayo Clin Proc 1989;64:577–86
   PubMed Web of Science ®Google Scholar
• Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227–31
   PubMed Web of Science ®Google Scholar
• Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993;43:655–61
   Google Scholar
• Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology 1995;45:1277–85
   Google Scholar
• McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121–7
   PubMed Web of Science ®Google Scholar
• Paty DW, Li DK. Interferon beta-1b is effective in relapsing- remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993;43:662–7
   Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285–94
   Google Scholar
• Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453–60
   PubMed Web of Science ®Google Scholar
• Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 2002;59:1496–506
   PubMed Web of Science ®Google Scholar
• Trojano M, Liguori M, Paolicelli D, et al. Interferon beta in relapsing-remitting multiple sclerosis: an independent post- marketing study in southern Italy. Mult Scler 2003;9:451–7
   PubMed Web of Science ®Google Scholar
• Limmroth V, Kalski G. Quality assessment in multiple sclerosis therapy – QUASIMS – comparative study to assess the efficacy and tolerability of interferon beta for relapsing-remitting multiple sclerosis (RRMS). Mult Scler 2003;9:S29
   Google Scholar
• Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta 1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon- beta 1a subcutaneously in multiple sclerosis. Ann Neurol 1999;46:197–206
   Google Scholar
• Palace J. Comparative study of IFN beta-1a 44 mcg tiw and 30 mcg qw: final evidence results. Mult Scler 2003;9:S24
   Google Scholar
• Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 2002;24:1720–40, discussion 1719
   Google Scholar
• Wandinger KP, Lunemann JD, Wengert O, et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 2003;361:2036–43
   PubMed Web of Science ®Google Scholar
• Gilli F, Bertolotto A, Sala A, et al. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN- beta mediated suppression of MMPs. Brain 2004;127:259–68
   PubMed Web of Science ®Google Scholar
• Goodkin DE. Interferon beta-1b. Lancet 1994;344:1057–60
   PubMed Web of Science ®Google Scholar
• Arnon R, Sela M. Immunomodulation by the copolymer glatiramer acetate. J Mol Recognit 2003;16:412–21
   PubMed Web of Science ®Google Scholar
• Goodin DS, Arnason BG, Coyle PK, et al. The use of mitox- antrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Sub- committee of the American Academy of Neurology. Neurology 2003;61:1332–8
   PubMed Web of Science ®Google Scholar
• Sackett DL. Rules of evidence and clinical recommendations for the management of patients. Can J Cardiol 1993;9:487–9
   PubMed Web of Science ®Google Scholar
• Clanet M, Radue EW, Kappos L, et al. A randomized, double- blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002;59:1507–17
   PubMed Web of Science ®Google Scholar
• Malucchi S, Sala A, Gilli F, et al. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology 2004;62:2031–7
   PubMed Web of Science ®Google Scholar
• Runkel L, De Dios C, Karpusas M, et al. Mapping of IFN-beta epitopes important for receptor binding and biologic activation: comparison of results achieved using antibody-based methods and alanine substitution mutagenesis. J Interferon Cytokine Res 2001;21:931–41
   PubMed Web of Science ®Google Scholar
• Bellomi F, Scagnolari C, Tomassini V, et al. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci 2003;215:3–8
   PubMed Web of Science ®Google Scholar
• Hartung HP, Munschauer 3rd FE. Assessment and management of neutralizing antibodies in patients with multiple sclerosis. J Neurol 2004;251\(Suppl 2):II40–2
   Google Scholar
• Perini P, Calabrese M, Biasi G, et al. The clinical impact of interferon beta antibodies in relapsing-remitting MS. J Neurol 2004;251:305–9
   PubMed Web of Science ®Google Scholar
• Polman C, Kappos L, White R, et al. Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology 2003;60:37–43
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003;362: 1184–91
   PubMed Web of Science ®Google Scholar
• Bertolotto A, Malucchi S, Sala A, et al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 2002;73:148–53
   PubMed Web of Science ®Google Scholar
• Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998;50:1266–72
   Google Scholar
• Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498–504
   Google Scholar
• Rice G. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta. Arch Neurol 2001;58:1297–8
   PubMed Web of Science ®Google Scholar
• Ross C, Clemmesen KM, Svenson M, et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 2000;48:706–12
   Google Scholar
• Rice GP, Paszner B, Oger J, et al. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 1999;52:1277–9
   PubMed Web of Science ®Google Scholar
• Khan OA, Dhib-Jalbut SS. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive. Neurology 1998;51:1698–702
   PubMed Web of Science ®Google Scholar
• Salama HH, Hong J, Zang YC, et al. Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis. Brain 2003;126:2638–47
   PubMed Web of Science ®Google Scholar
• Vartanian TK, Zamvil SS, Fox E, et al. Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis. Neurology 2004;63(Suppl 5):S42–9
   PubMedGoogle Scholar
• Pachner AR. Anti-IFN-β antibodies in IFN-β-treated MS patients. Neurology 2003;61:S2–5
   Google Scholar
• Deisenhammer F, Schellekens H, Bertolotto A. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis. J Neurol 2004;251\(Suppl 2):II31–9
   Google Scholar
• World Health Organization. Department of vaccines and biologicals: standardization and validation of serological assays for the evaluation of immune responses to Neisseria meningitides serogroup A/C vaccines. World Health Organization, Available from http://www.who.int/vaccines-documents/DocsPDF99/ www9927.pdf [Accessed 30 May 2005]
   Google Scholar
• Pachner AR. An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients. Neurology 2003;61:1444–6
   PubMed Web of Science ®Google Scholar
• Gilli F, Marnetto F, Stefanuto G, et al. Comparison of three PCR assays for the evaluation of interferon-beta biological activity in patients with multiple sclerosis. Mol Diagn 2004;8:185–94
   PubMedGoogle Scholar
• Pachner AR, Bertolotto A, Deisenhammer F. Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB). Neurology 2003;61(Suppl 5):S24–6
   Google Scholar
• Bertolotto A. Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis. Curr Opin Neurol 2004;17:241–6
   PubMed Web of Science ®Google Scholar
• Schellekens H. The immunogenicity of biopharmaceuticals. Neurology 2003;61(Suppl 5):S11–2
   PubMedGoogle Scholar
• Porter S. Human immune response to recombinant human proteins. J Pharm Sci 2001;90:1–11
   PubMed Web of Science ®Google Scholar
• Bendtzen K. Anti-IFN BAb and NAb antibodies: a minireview. Neurology 2003;61(Suppl 5):S6–10
   PubMedGoogle Scholar
• Evidence of interferon beta-1a dose response in relapsing- remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group. Neurology 1999;53:679–86
   Google Scholar
• Bertolotto A, Deisenhammer F, Gallo P, et al. Immunogenicity of interferon beta: differences among products. J Neurol 2004;251\(Suppl 2):II15–24
   Google Scholar
• Bertolotto A, Malucchi S, Milano E, et al. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology 2000;48:95–100
   PubMedGoogle Scholar
• PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56:1628–36
   PubMed Web of Science ®Google Scholar
• Bertolotto A, Gilli F, Sala A, et al. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 2003;60:634–9
   PubMed Web of Science ®Google Scholar
• Deisenhammer F, Reindl M, Harvey J, et al. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999;52:1239–43
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Ross C, Clemmesen KM, et al. Antibodies to IFN-beta: the Danish National IFN-beta Project. Neurology 2003;61(Suppl 5):S27–8
   PubMedGoogle Scholar
• Pachner AR, Oger J, Palace J. The measurement of antibodies binding to IFNbeta in MS patients treated with IFNbeta. Neurology 2003;61(Suppl 5):S18–20
   Google Scholar
• Sorensen PS, Koch-Henriksen N, Ross C, et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005;65:33–9
   PubMed Web of Science ®Google Scholar
• Kappos L, Clanet M, Sandberg-Wollheim M, et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005;65: 40–7
   Google Scholar
• Giovannoni G, Goodman A. Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice? Neurology 2005;65:6–8
   PubMed Web of Science ®Google Scholar
• Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European study group on interferon beta-1b in secondary progressive MS. Lancet 1998;352:1491–7
   Google Scholar
• Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology 1996;47:889–94
   Google Scholar
• Paty DW, Goodkin D, Thompson A, et al. Guidelines for physicians with patients on IFN beta-1b: the use of an assay for neutralizing antibodies (NAB). Neurology 1996;47:865–6
   PubMed Web of Science ®Google Scholar
• Sala A CM, Malucchi S. Disappearance of neutralizing antibodies to interferon-beta in multiple sclerosis treated patients. Mult Scler 2003;9:S74
   Google Scholar
• Lusher JM, Lee CA, Kessler CM, et al. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003; 9:38–49
   PubMed Web of Science ®Google Scholar
• Thorner M, Rochiccioli P, Colle M, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab 1996;81:1189–96
   PubMed Web of Science ®Google Scholar
• Pirazzoli P, Cacciari E, Mandini M, et al. Follow-up of antibodies to growth hormone in 210 growth hormone-deficient children treated with different commercial preparations. Acta Paediatr 1995;84:1233–6
   PubMed Web of Science ®Google Scholar
• Vartanian T. An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis. Clin Ther 2003;25:105–18
   PubMed Web of Science ®Google Scholar
• Giovannoni G. Strategies to treat and prevent the development of neutralizing anti-interferon-beta antibodies. Neurology 2003;61(Suppl 5):S13–7
   PubMedGoogle Scholar
• Myhr KM, Ross C, Nyland HI, et al. Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive. Neurology 2000;55:1569–72
   PubMed Web of Science ®Google Scholar
• Pozzilli C, Antonini G, Bagnato F, et al. Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis. J Neurol 2002;249:50–6
   PubMed Web of Science ®Google Scholar
• Durelli L, Ricci A. Anti-interferon antibodies in multiple sclerosis. molecular basis and their impact on clinical efficacy. Front Biosci 2004;9:2192–204
   PubMed Web of Science ®Google Scholar
• Spindler M, Weilbach F, Beer M, et al. Non-invasive functional and biochemical assessment of mitoxantrone cardiotoxicity in patients with multiple sclerosis. J Cardiovasc Pharmacol 2003;42:680–7
   PubMed Web of Science ®Google Scholar
• Healthwise – Kaiser Permanente. Mitoxantrone for multiple sclerosis. Available from http://prospectivemembers.kaiserpermanente.org/kpweb/healthency.do?body=drugdetail/tf4627/tf4627&navtop=drugdetail/tf4627/navtop.jsp&topic=Mitoxantrone+for+multiple+sclerosis&engine=sitematch&group= kp-healthencyc [Accessed 30 May 2005]
   Google Scholar
• Francis GS, Rice GP, Alsop JC. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005;65: 48–55
   Google Scholar
• Gneiss C, Reindl M, Lutterotti A, et al. Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity. Mult Scler 2004;10:507–10
   PubMed Web of Science ®Google Scholar
• Herndon RM, Jacobs LD, Coats ME, et al. Results of an ongoing, open-label, safety-extension study of interferon beta-1a (Avonex) treatment in multiple sclerosis. Int J MS Care 1999;2:1–6
   Google Scholar
• Ure DR, Rodriguez M. Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating disease. Faseb J 2002;16:1260–2
   PubMed Web of Science ®Google Scholar
• Rizvi SA, Bashir K. Other therapy options and future strategies for treating patients with multiple sclerosis. Neurology 2004;63(Suppl 6):S47–54
   PubMedGoogle Scholar
• The Biology Project – University of Arizona. Introduction to ELISA Activity. Available from http://www.biology.arizona.edu/immunology/activities/elisa/main.html [Accessed 30 May 2005]
   Google Scholar